Macular Edema Associated With Fingolimod - American …
2012年4月1日 · Fingolimod (Gilenya) hinders the trafficking of lymphocytes involved in the immune-mediated process of MS. Despite its generally favorable safety profile, fingolimod may cause macular edema in a subset of patients.
Gilenya: Uses, Dosage, Side Effects, Warnings - Drugs.com
2024年6月20日 · S1P receptor modulators, including Gilenya, have been associated with an increased risk of macular edema. Your healthcare provider should send you for an eye examination before starting treatment, 3 to 4 months into treatment, periodically thereafter, and any time there is a vision change.
Fingolimod-Associated Macular Edema - EyeWiki
Fingolimod is a disease-modifying therapy for relapsing-remitting multiple sclerosis (RRMS) that acts to modulate the sphingosine-1-phosphate receptor. Macular edema is a known dose-dependent side effect of fingolimod use that typically resolves upon discontinuation of the drug.
Gilenya (Fingolimod): Side Effects, for MS, Costs, and More - Healthline
2022年4月23日 · Specifically, Gilenya can cause macular edema, which is a fluid buildup in part of your eye called the retina. People who have this side effect usually have symptoms within the first 3 to 4...
Macular edema can cause some of the same vision symptoms as an MS attack (optic neuritis). You may not notice any symptoms with macular edema. Macular edema usually starts in the first...
symptoms with macular edema. If macular edema happens, it usually starts in the first 3 to 4 months after you start taking GILENYA. Your doctor should test your vision before you start taking...
5. A problem with your vision called macular edema. Macular edema can cause some of the same vision symptoms as a multiple sclerosis (MS) attack (optic neuritis). You may not notice any symptoms with macular edema. If macular edema happens, it usually starts in the first 3 to 4 months after you start taking GILENYA but can happen at any time.
Macular edema. Rarely, patients treated with Gilenya develop macular edema, manifested clinically as blurred vision. It usually develops within 3-6 months after starting Gilenya and improves or resolves with discontinuation of Gilenya. Patients with diabetes and uveitis are at increased risk for macular edema from Gilenya.
GILENYA at the first sign or symptom suggestive of PML. (5.3) •Macular Edema: Increases the risk of macular edema. Obtain a baseline evaluation of the fundus, including the macula, near the start of treatment with GILENYA. Conduct an evaluation of the fundus, including the macula, 3 to 4 months after treatment start, periodically
Gilenya - MS Protocols
Patients with diabetes mellitus or a history of uveitis are at increased risk of macular edema and should undergo an ophthalmic evaluation prior to initiating GILENYA® therapy. Questran should be used to fully eliminate teriflunamide when switching from it to Gilenya.